146 related articles for article (PubMed ID: 26626277)
1. Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates.
Mulu A; Maier M; Liebert UG
J Transl Med; 2015 Dec; 13():377. PubMed ID: 26626277
[TBL] [Abstract][Full Text] [Related]
2. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea.
Kim JY; Kim EJ; Choi JY; Kwon OK; Kim GJ; Choi SY; Kim SS
Clin Microbiol Infect; 2011 Aug; 17(8):1155-9. PubMed ID: 20946407
[TBL] [Abstract][Full Text] [Related]
4. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M; Chiarella J; Kozal MJ
Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
[TBL] [Abstract][Full Text] [Related]
5. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
[TBL] [Abstract][Full Text] [Related]
6. Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.
Wallis CL; Viana RV; Saravanan S; Silva de Jesus C; Zeh C; Halvas EK; Mellors JW
J Virol Methods; 2017 Mar; 241():41-45. PubMed ID: 27993614
[TBL] [Abstract][Full Text] [Related]
7. Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.
Dimonte S; Babakir-Mina M; Aquaro S; Perno CF
Infection; 2013 Dec; 41(6):1097-102. PubMed ID: 23620062
[TBL] [Abstract][Full Text] [Related]
8. Low level of HIV-1C integrase strand transfer inhibitor resistance mutations among recently diagnosed ART-naive Ethiopians.
Kiros M; Tefera DA; Andualem H; Geteneh A; Tesfaye A; Woldemichael TS; Kidane E; Alemayehu DH; Maier M; Mihret A; Abegaz WE; Mulu A
Sci Rep; 2023 Apr; 13(1):6546. PubMed ID: 37085698
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.
Chang SY; Lin PH; Cheng CL; Chen MY; Sun HY; Hsieh SM; Sheng WH; Su YC; Su LH; Chang SF; Liu WC; Hung CC; Chang SC
Sci Rep; 2016 Oct; 6():35779. PubMed ID: 27779200
[TBL] [Abstract][Full Text] [Related]
10. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
[TBL] [Abstract][Full Text] [Related]
11. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
12. HIV-1C proviral DNA for detection of drug resistance mutations.
Huruy K; Mulu A; Liebert UG; Maier M
PLoS One; 2018; 13(10):e0205119. PubMed ID: 30286160
[TBL] [Abstract][Full Text] [Related]
13. An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors.
Theys K; Libin PJK; Van Laethem K; Abecasis AB
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109980
[TBL] [Abstract][Full Text] [Related]
14. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase.
Myers RE; Pillay D
J Virol; 2008 Sep; 82(18):9228-35. PubMed ID: 18596095
[TBL] [Abstract][Full Text] [Related]
15. Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.
Huruy K; Maier M; Mulu A; Liebert UG
J Med Virol; 2015 Jun; 87(6):978-84. PubMed ID: 25649964
[TBL] [Abstract][Full Text] [Related]
16. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil.
Passaes CB; Guimarães ML; Fernandez SL; Lorete Rdos S; Teixeira SL; Fernandez JC; Morgado MG
J Acquir Immune Defic Syndr; 2009 May; 51(1):7-12. PubMed ID: 19262402
[TBL] [Abstract][Full Text] [Related]
17. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.
Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Rinke de Wit TF; Paredes R
J Antimicrob Chemother; 2018 May; 73(5):1167-1172. PubMed ID: 29462322
[TBL] [Abstract][Full Text] [Related]
18. Clade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in Ethiopia.
Mulu A; Lange T; Liebert UG; Maier M
BMC Infect Dis; 2014 Mar; 14():158. PubMed ID: 24655349
[TBL] [Abstract][Full Text] [Related]
19. Primary resistance to integrase strand-transfer inhibitors in Europe.
Casadellà M; van Ham PM; Noguera-Julian M; van Kessel A; Pou C; Hofstra LM; Santos JR; Garcia F; Struck D; Alexiev I; Bakken Kran AM; Hoepelman AI; Kostrikis LG; Somogyi S; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Staneková D; Stanojevic M; Van Laethem K; Zidovec Lepej S; Clotet B; Boucher CA; Paredes R; Wensing AM;
J Antimicrob Chemother; 2015 Oct; 70(10):2885-8. PubMed ID: 26188038
[TBL] [Abstract][Full Text] [Related]
20. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
